| 9.9999997E-5 -0 (-0%) | 01-08 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to creating and marketing highly specific diagnostic tools that leverage the immune system, as well as therapeutic agents also based on immune principles. Its operations are divided into two primary divisions: Diagnostic Substances and Therapeutic Development Programs. Central to its efforts is the Manocept platform, designed to selectively bind to the CD206 mannose receptor found on activated macrophages. This innovative platform enables various diagnostic techniques, such as single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and intra-operative or optical-fluorescence detection. Additionally, it facilitates the targeted delivery of therapeutic agents to macrophages, addressing a spectrum of immune- and inflammation-related conditions. The company's pipeline includes several key candidates for rheumatoid arthritis (RA). NAV3-31 has successfully concluded Phase IIb clinical trials, where its imaging repeatability, reproducibility, and stability were assessed. These trials also investigated the potential of Tc99m tilmanocept imaging to guide anti-tumor necrosis factor alpha therapy for individuals suffering from moderate to severe RA. Furthermore, NAV3-35 is currently undergoing a Phase IIb clinical trial for RA imaging, while NAV3-33 is advancing through Phase III clinical trials for RA. Another compound, NAV3-32, is in Phase 2b trials, focusing on RA-affected joints. Beyond RA, Navidea is exploring the utility of Tc99m tilmanocept for various other applications, including cardiovascular conditions, Kaposi's sarcoma, tuberculosis, and additional immunotherapeutic uses. Originally established as Neoprobe Corporation, the company adopted its current name, Navidea Biopharmaceuticals, Inc., in January 2012. Founded in 1983, its corporate headquarters are located in Dublin, Ohio.
Wed, 02 Sep 2026
Navidea Biopharmaceuticals Inc. (NAVB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Wed, 21 May 2025
Navidea Biopharmaceuticals delays reverse stock split decision - Investing.com
Thu, 24 Apr 2025
Navidea Biopharm (NAVB) Stock Price, News & Analysis - Stock Titan
Wed, 24 May 2023
Navidea Biopharmaceuticals Inc (NAVB) News, Articles, Events & Latest Updates - Stocktwits
Sat, 21 Jan 2023
Navidea Biopharmaceuticals Inc (NAVB) sentiment score, message volume, participation score and buzz level - Stocktwits
Wed, 30 Nov 2022
Navidea Biopharmaceuticals Inc (NAVB) Fundamental & Financial Data - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|